Financial Performance - The net profit attributable to ordinary shareholders for 2021 was RMB 24,271,104.15, with a proposed cash dividend of RMB 1 per 10 shares[6]. - As of December 31, 2021, the company's distributable profits amounted to RMB 110,364,632.53, with no profit distribution in 2020[6]. - The total number of shares for dividend distribution is 258,382,608, leading to a total cash dividend payout of RMB 25,838,260.80 (including tax)[6]. - The company's operating revenue for 2021 was approximately CNY 312.64 million, representing a year-over-year increase of 3.82% compared to CNY 301.12 million in 2020[22]. - The net profit attributable to shareholders decreased by 59.48% to CNY 24.27 million from CNY 59.90 million in the previous year[22]. - The basic and diluted earnings per share fell by 70.97% to CNY 0.09, down from CNY 0.31 in 2020[23]. - The net profit after deducting non-recurring gains and losses dropped by 89.6% to CNY 5.47 million compared to CNY 52.55 million in 2020[22]. - The company's total assets increased by 12.58% to CNY 1.36 billion from CNY 1.21 billion in 2020[22]. - The weighted average return on equity decreased by 11.2 percentage points to 2.55% from 13.75% in 2020[23]. - The net assets attributable to shareholders increased by 2.21% to CNY 960.63 million from CNY 939.82 million in 2020[22]. - The overall gross profit margin decreased to 31.49%, down 13.71 percentage points from the previous year[75]. - The net profit attributable to the parent company was 24.27 million RMB, a decline of 59.48% year-on-year[79]. Research and Development - Research and development expenses accounted for 16.4% of operating revenue, an increase of 6.14 percentage points from 10.26% in 2020[23]. - R&D investment totaled ¥51,257,251.58, representing a 65.95% increase year-on-year, with R&D expenses accounting for 16.4% of operating revenue, up from 10.26%[54][55]. - The number of R&D personnel increased to 99, accounting for 23% of the total workforce, up from 21% in the previous year[63]. - R&D personnel compensation totaled 2,281.27 million RMB, with an average salary of 23.04 million RMB, reflecting an increase from 20.10 million RMB in the prior year[63]. - The company has applied for a total of 110 patents, including 57 invention patents, with 23 new patent applications during the reporting period[51]. Operational Challenges - The company faced challenges due to the ongoing impact of the pandemic, changes in exchange rates, and increased costs related to product delivery and raw materials[23]. - The decline in profit was primarily due to increased R&D investment, higher costs in domestic aviation business, and the impact of medical procurement policies[33]. - The company faces risks from increased competition in the aviation engine parts manufacturing sector due to potential new entrants[76]. - Fluctuations in the USD/RMB exchange rate could impact the company's performance, as foreign sales accounted for 28.94% of total revenue[77]. Market Outlook - The Chinese aviation market is projected to receive 9,084 aircraft over the next 20 years, valued at approximately 1.4 trillion USD, indicating strong long-term demand for aviation engine components[36]. - The market for aviation engines in China is expected to deliver a total of 15,000 units over the next 20 years, with a market value of 260 billion USD[36]. - The orthopedic implant market in China is projected to reach 50.5 billion yuan by 2023, with a compound annual growth rate of 14.2% from 2019 to 2023[39]. - The company is positioned as a midstream supplier in the aviation industry chain, primarily providing finished components[41]. Strategic Initiatives - The company signed a strategic cooperation agreement with China Aviation Engine Corporation on January 29, 2021, to establish a long-term partnership[44]. - The company plans to invest 83,237.40 million RMB in expanding the capacity of key components for aircraft engines, with 6,968.14 million RMB already invested in the reporting period[114]. - The company aims to increase its actual supply share to over 50% from 35% in the partnership with Safran for blade procurement, with delivery volumes expected to return to pre-pandemic levels by 2022[123]. - The company plans to enhance production efficiency and quality management, focusing on strategic customer needs and new product development[129]. Governance and Compliance - The company has received a standard unqualified audit report from the accounting firm Tianye[5]. - The company is committed to ensuring the authenticity, accuracy, and completeness of the annual report[4]. - The company has established a governance structure that operates effectively in accordance with relevant laws and regulations, enhancing the fairness and rationality of board decisions[134]. - The company has not encountered any significant differences in governance compared to regulations set by the China Securities Regulatory Commission[134]. - The company has implemented a robust supplier management system to foster long-term partnerships based on mutual benefit and quality assurance[187]. Social Responsibility - The company donated materials worth 0.42 million yuan for pandemic relief and 9.6 million yuan to support rural revitalization efforts in Sanmenxia, Henan Province[180]. - The company actively participates in social responsibility initiatives, including donations and support for community welfare during the COVID-19 pandemic[172]. - The company has established a comprehensive environmental management system, including regulations for hazardous waste management and pollution control[177]. Employee and Management - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.2764 million RMB[149]. - The company has a structured approach to determining the remuneration of senior management based on performance assessments and company profitability[149]. - The company has seen a change in the financial director position due to personal reasons, with Huang Qin being appointed following a job adjustment[150]. - The company has maintained a stable management team with no significant changes in shareholding or remuneration during the reporting period[139].

2022 年第一季度报告 证券代码：688510 证券简称：航亚科技 无锡航亚科技股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | | | 单位：元 币种：人民币 | | | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 本报告期比上年同 | | | | | | 期增减变动幅度(%) | | | | 营业收入 | 61,813,276.31 | | | 5.64 | | 归属于上市公司股东的净利润 | 1,928,475.31 | | | -27.48 | | 归属于上市公司股 ...

Financial Performance - The net profit attributable to ordinary shareholders for 2021 was RMB 24,271,104.15, with a proposed cash dividend of RMB 1 per 10 shares[6]. - As of December 31, 2021, the company's distributable profits amounted to RMB 110,364,632.53, with no profit distribution in 2020[6]. - The total number of shares for dividend distribution is 258,382,608, leading to a total proposed cash dividend of RMB 25,838,260.80 (including tax)[6]. - The company's operating revenue for 2021 was approximately ¥312.64 million, representing a year-over-year increase of 3.82% compared to ¥301.12 million in 2020[22]. - The net profit attributable to shareholders decreased by 59.48% to ¥24.27 million from ¥59.90 million in the previous year[22]. - The basic and diluted earnings per share fell by 70.97% to ¥0.09 from ¥0.31 in 2020[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses dropped by 89.6% to ¥5.47 million from ¥52.55 million in 2020[22]. - Operating profit decreased to 21.53 million yuan, down 68.44% compared to the previous year[33]. - The company reported a total revenue of 10,120 million RMB for the year, with a net profit of 3,108 million RMB, indicating a significant decline compared to the previous year[60]. Operational Risks and Challenges - The company has outlined various operational risks and corresponding countermeasures in the report[4]. - The company has not yet achieved profitability since its listing[4]. - The company faced challenges due to the ongoing impact of the pandemic, changes in exchange rates, and increased costs related to raw materials and external procurement[23]. - The company is exposed to risks related to quality control and raw material price fluctuations, which could adversely affect profitability[71]. - The company anticipates increased competition in the aviation engine component manufacturing sector due to potential market entry by new players[72]. Research and Development - Research and development expenses accounted for 16.4% of operating revenue, an increase of 6.14 percentage points from 10.26% in 2020[23]. - R&D investment totaled approximately ¥51.26 million in 2021, a significant increase of 65.95% year-on-year, representing 16.4% of total revenue[54][55]. - The number of R&D personnel increased to 99, representing 23% of the total workforce, up from 21% in the previous year[63]. - The total compensation for R&D personnel rose to 2,281.27 million RMB, with an average salary of 23.04 million RMB, compared to 20.10 million RMB last year[63]. - The company is focusing on research and development of new technologies to enhance product offerings and improve market competitiveness[129]. Strategic Partnerships and Collaborations - The company signed a strategic cooperation agreement with China Aviation Engine Corporation on January 29, 2021, to establish a long-term partnership[44]. - The company has established stable partnerships with major clients in the aviation engine and medical device sectors, ensuring ongoing business growth[65]. - The company aims to increase its international business share from 35% to over 50% in the supply of blades to Safran, with blade delivery volumes expected to return to pre-pandemic levels by 2022[111]. Market Outlook and Expansion - The Chinese aviation market is expected to receive 9,084 aircraft over the next 20 years, valued at approximately 1.4 trillion USD[36]. - The demand for aviation engine components in China is projected to reach 15,000 units over the next 20 years, with a market value of 260 billion USD[36]. - The orthopedic implant market in China is expected to reach 50.5 billion yuan by 2023, with a compound annual growth rate of 14.2% from 2019 to 2023[39]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2023[132]. Corporate Governance and Management - The company emphasizes a strong governance structure, ensuring fair decision-making and compliance with legal requirements[170]. - The company has a structured decision-making process for remuneration, involving the compensation and assessment committee and the board of directors[137]. - The company has a diverse board with members holding positions in various other organizations, enhancing its governance and strategic oversight[134]. - The company held three shareholder meetings during the reporting period, with all resolutions legally valid and properly disclosed[125]. Environmental and Social Responsibility - The company achieved zero wastewater discharge through its internal treatment processes, ensuring compliance with environmental standards[164]. - The company donated materials worth 0.42 million yuan for pandemic relief and 9.6 million yuan for rural revitalization efforts in Sanmenxia, Henan Province[168]. - The company actively participates in social responsibility initiatives, including donations and support for community welfare during the COVID-19 pandemic[160]. Future Commitments and Strategies - The company plans to invest 100 million in R&D over the next two years to drive innovation and improve product offerings[132]. - The company is committed to enhancing ESG practices and transparency in its operations, aligning with regulatory requirements[160]. - The company has outlined its strategy for market expansion and potential mergers and acquisitions in its future plans[189].

2021 年第三季度报告 证券代码：688510 证券简称：航亚科技 无锡航亚科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 （一）主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | 年初至报告期末 | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 79,709,496.53 | 20.56 | 211,187,593.40 | -4.29 ...

Financial Performance - The company's operating revenue for the first half of 2021 was RMB 131,478,096.87, a decrease of 14.92% compared to RMB 154,533,617.24 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was RMB 10,494,085.73, down 64.12% from RMB 29,247,438.95 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 4,792,276.02, a decline of 83.49% compared to RMB 29,034,194.67 in the same period last year[19]. - The net cash flow from operating activities was negative RMB 29,668,740.52, compared to negative RMB 2,608,119.71 in the previous year, representing a decrease of 1,037.55%[19]. - The company's basic earnings per share decreased by 73.09% to CNY 0.0406 compared to the same period last year[20]. - Operating revenue decreased by 14.92%, primarily due to a 27.37% decline in international business and delays in domestic aviation engine deliveries[20]. - The weighted average return on net assets decreased by 5.85 percentage points to 1.11%[20]. - The net cash flow from operating activities dropped by 1,037.55% due to increased procurement payments and reduced cash recovery from sales[20]. Research and Development - R&D investment accounted for 18.31% of operating revenue, an increase of 7.94 percentage points compared to the previous year[20]. - The company focuses on independent research and development, with key projects involving synchronous design for critical components in collaboration with major engine design institutions[33]. - The company has applied for a total of 101 patents, including 46 invention patents, and has authorized 64 patents, with 13 being invention patents[56]. - Research and development expenses increased by 50.20% from the previous period, totaling approximately ¥24.07 million, which represents 18.31% of total revenue[60]. - The company has developed advanced core technologies, including precision forging near-net-shape technology and adaptive polishing technology for complex surfaces[50]. Market Position and Strategy - The aviation engine industry is experiencing significant growth, with China projected to become the largest civil aircraft market in the next 20 years, creating opportunities for domestic manufacturers[38]. - The orthopedic implant market in China is growing rapidly, with significant potential for domestic manufacturers to replace imported brands, particularly in spine and joint segments[43]. - The company is positioned to benefit from the increasing international outsourcing market for aviation engine components due to its recognized product quality and high production efficiency[41]. - The company is focusing on strategic customers and high-end markets to maintain its position in the domestic market while advancing its international strategy[83]. - The company is actively expanding its product range and enhancing its technological capabilities to support the development of advanced aerospace components[66]. Production and Operations - The company has established a direct sales model, focusing on core strategic customers and requiring quality certifications to supply products[28]. - The production model is based on a make-to-order approach, ensuring strict adherence to quality standards and customer requirements[31]. - The company has implemented a digital factory construction to enhance production efficiency and product quality, achieving automated rapid mold change based on accumulated production data[32]. - The company has established three business segments: compressor blades, rotating parts, and medical orthopedics, supported by a complete engineering and industrialization platform[36]. - The company emphasizes quality management, implementing a solid quality management system and regular training to enhance quality awareness among employees[37]. Financial Position and Investments - The total assets at the end of the reporting period were RMB 1,262,093,477.29, reflecting a growth of 4.24% from RMB 1,210,801,572.29 at the end of the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were RMB 950,312,031.55, an increase of 1.12% from RMB 939,817,945.82 at the end of the previous year[19]. - The company has invested a total of 8,480 million RMB in various projects, with 1,522 million RMB invested in the current period and a cumulative investment of 3,086 million RMB[66]. - The company has made a new equity investment of ¥105 million during the reporting period[99]. - The company has established Guizhou Hangya Technology Co., Ltd. with a total investment of RMB 300 million, where the company invested RMB 210 million and has completed an initial investment of RMB 105 million[142]. Corporate Governance and Compliance - The company appointed Huang Qin as the new Chief Financial Officer and Wei Zhe as the new Secretary of the Board, following the resignation of the previous CFO due to health reasons and the Secretary's reassignment[111]. - The company has committed to maintaining a lock-up period for major shareholders and core technical personnel for 36 months post-IPO, with additional restrictions on share sales for 2 years thereafter[121]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[118]. - The company has made commitments regarding the reduction of related party transactions, as per the announcements on the Shanghai Stock Exchange[123]. - The company has no significant litigation or arbitration matters during the reporting period[138].

2021 年半年度报告 公司代码：688510 公司简称：航亚科技 无锡航亚科技股份有限公司 2021 年半年度报告 1 / 147 2021 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，具体内容详 见本报告第三节"管理层讨论与分析"之"五、风险因素"，敬请广大投资者查阅。 三、公司全体董事出席董事会会议。 四、本半年度报告未经审计。 五、公司负责人严奇、主管会计工作负责人黄勤及会计机构负责人（会计主管人员）王萍声明： 保证半年度报告中财务报告的真实、准确、完整。 六、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无。 七、是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述均不构成公司对投资者的实质承诺，投 资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间 ...

Financial Performance - The company reported no profit distribution for the fiscal year 2020, considering its ongoing development phase and significant capital needs[6]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the fiscal year, representing a 15% year-over-year growth[13]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion CNY[15]. - The company's operating revenue for 2020 was CNY 301,120,950.84, representing a year-on-year increase of 16.89% compared to CNY 257,604,361.92 in 2019[23]. - The net profit attributable to shareholders for 2020 was CNY 59,896,575.83, which is a 41.98% increase from CNY 42,185,477.50 in 2019[23]. - The basic earnings per share for 2020 was CNY 0.3091, up 41.98% from CNY 0.2177 in 2019[25]. - The total assets at the end of 2020 were CNY 1,210,801,572.29, a 92.87% increase from CNY 627,776,943.55 at the end of 2019[24]. - The net assets attributable to shareholders increased by 131.71% to CNY 939,817,945.82 in 2020 from CNY 405,609,223.03 in 2019[24]. - The cash flow from operating activities for 2020 was CNY 52,604,695.15, a decrease of 8.51% compared to CNY 57,494,852.88 in 2019[23]. - The company achieved an annual revenue of 301.12 million yuan, representing a year-on-year growth of 16.89%[85]. - Operating profit reached 68.23 million yuan, an increase of 50.33% compared to the previous year[85]. - Net profit attributable to shareholders was 59.90 million yuan, up by 41.98% year-on-year[85]. Research and Development - The company is investing in R&D, allocating 100 million CNY for the development of innovative materials and processes[20]. - Research and development expenses accounted for 10.26% of operating revenue in 2020, down from 11.93% in 2019[25]. - The company applied for a total of 29 patents during the reporting period, including 19 invention patents, and received 27 patents, with 7 being invention patents[62]. - Total R&D expenditure for the year was approximately ¥30.89 million, representing a 0.52% increase from the previous year[64]. - The company has achieved NADCAP certification for its special processes, indicating compliance with international aerospace quality standards[61]. - The company has developed several core technologies, including adaptive polishing technology for blade edges, which significantly improves production yield and reduces overall manufacturing costs[58]. - The company has completed the development of key technologies for titanium alloy hip joints, with results expected to be applied in various customer projects[6]. Market Expansion and Strategy - The company is expanding its market presence, targeting an increase in international sales by 30% in the upcoming year[17]. - A strategic acquisition of a smaller competitor is anticipated to be finalized by Q2 2021, expected to add 200 million CNY in annual revenue[18]. - The company plans to enhance its digital transformation efforts, focusing on ERP and MES systems to streamline operations and improve efficiency[22]. - The company is focusing on expanding its domestic business in aerospace engines, benefiting from strong demand in the domestic aviation manufacturing sector[89]. - The company is actively developing new products in the orthopedic field, including tibial trays and bone plates, to enhance market share amid increasing competition[89]. - The company is considering strategic acquisitions to bolster its technology portfolio, with a budget of 100 million allocated for potential deals[142]. Corporate Governance and Compliance - The company does not have any special arrangements for corporate governance[9]. - The company has established a robust corporate governance structure to protect the rights of shareholders and creditors, ensuring compliance with relevant laws and regulations[177]. - The company has committed to improving compliance management across financial, legal, and environmental health and safety aspects[134]. - The management team confirmed that no shares will be transferred or managed by others during the lock-up period of 36 months post-IPO[145]. - The company will adhere to regulations regarding share reduction plans after the lock-up period expires, ensuring compliance with the China Securities Regulatory Commission[146]. Operational Efficiency - The implementation of advanced manufacturing technologies is projected to reduce production costs by 15%[19]. - The company is enhancing production efficiency and product quality through the construction of a digital factory and continuous process improvement based on accumulated production data[37][38]. - The company has established a comprehensive supply chain management system, ensuring a wide selection of qualified suppliers for raw materials[36]. - The company has a strong emphasis on continuous technological innovation and process optimization to meet the high standards of the aerospace and medical industries[38]. Social Responsibility - The company donated RMB 300,000 to support COVID-19 prevention efforts in the local community[173]. - The company has actively participated in local poverty alleviation activities in Wuxi City[173]. - The company aims to continue its long-term commitment to poverty alleviation as part of its corporate social responsibility initiatives[176]. Shareholder Information - The company successfully listed on the Sci-Tech Innovation Board on December 16, 2020, raising funds to support future development[85]. - The total number of ordinary shares before the recent changes was 193,782,608, with an increase of 14,333,271 shares, bringing the total to 208,115,879 shares[184]. - The company completed its initial public offering (IPO) of 64.6 million shares, increasing the total share capital from 193,782,608 to 258,382,608 shares[186]. - The IPO price was set at 8.7 RMB per share, raising a total of approximately 564.42 million RMB[191]. - The company has a total of 10 major shareholders, with the top three holding a combined 30.65% of shares[195].

Financial Performance - Operating revenue decreased by 12.87% to CNY 58,512,400.79 year-on-year[5] - Net profit attributable to shareholders decreased by 77.11% to CNY 2,659,376.27 compared to the same period last year[5] - Basic earnings per share dropped by 82.83% to CNY 0.0103 compared to the previous year[5] - The company's operating revenue for Q1 2021 was CNY 58,512,400.79, a decrease of 12.87% compared to CNY 67,156,897.26 in the same period last year[11] - The net profit attributable to shareholders of the parent company was CNY 2,659,376.27, down 77.11% from CNY 11,619,475.10 in the previous year[12] - Net profit for Q1 2021 was ¥2,564,275.38, down 77.8% from ¥11,536,040.10 in Q1 2020[23] - Total profit for Q1 2021 was ¥3,083,924.60, a decrease of 76.3% from ¥13,022,444.91 in Q1 2020[23] Cash Flow - The net cash flow from operating activities was negative at CNY -29,756,181.28, a decline of 79.20% year-on-year[5] - Cash flow from operating activities showed a net outflow of CNY 29,756,181.28, a decline of 79.20% compared to CNY -16,604,856.35 in the same period last year[12] - The net cash flow from operating activities for Q1 2021 was -29,756,181.28 RMB, compared to -16,604,856.35 RMB in Q1 2020, indicating a decline of approximately 79.5% year-over-year[28] - The net cash flow from investing activities was -43,492,833.50 RMB in Q1 2021, compared to -18,014,579.72 RMB in Q1 2020, reflecting a decline of approximately 141.4% year-over-year[31] - Cash inflow from operating activities totaled 25,406,482.11 RMB in Q1 2021, down from 32,470,082.51 RMB in Q1 2020, a decrease of approximately 21.6%[30] Assets and Liabilities - Total assets increased by 2.94% to CNY 1,246,435,474.59 compared to the end of the previous year[5] - Current assets totaled CNY 800,569,884.92, up from CNY 779,405,370.97, indicating an increase of about 2.2%[15] - Total liabilities increased to CNY 303,330,154.66 from CNY 270,260,527.74, marking a rise of approximately 12.2%[16] - Short-term borrowings increased to CNY 56,441,466.38 from CNY 40,069,933.88, representing a growth of about 40.7%[16] - Non-current assets totaled CNY 445,865,589.67, up from CNY 431,396,201.32, indicating an increase of approximately 3.4%[15] Research and Development - R&D investment as a percentage of operating revenue increased by 3.93 percentage points to 14.68%[5] - Research and development expenses increased by 19.05% to CNY 8,591,652.85 from CNY 7,216,737.90 year-on-year[11] - The company’s management indicated a focus on increasing R&D investment to drive future growth despite current revenue challenges[22] Shareholder Information - The total number of shareholders reached 10,755 by the end of the reporting period[9] - The top shareholder, Yan Qi, holds 14.44% of the shares, totaling 37,317,391 shares[9] Other Financial Metrics - The company reported a total of CNY 562,280.92 in non-recurring gains and losses for the period[8] - The company's short-term borrowings increased by 40.86% to CNY 56,441,466.38 from CNY 40,069,933.88 year-on-year[11] - The company reported a credit impairment loss of ¥-497,751.00, an improvement from ¥-713,043.03 in Q1 2020[22] - The company’s investment income dropped to CNY 51,487.37, a decrease of 100% compared to the previous year, attributed to reduced financial management income[12]